Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMTI NASDAQ:IMGN NASDAQ:PRLD NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMTIApplied Molecular Transport$0.26$0.24$0.13▼$0.84$10.87M2.28470,969 shsN/AIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shs40 shsPRLDPrelude Therapeutics$1.04-10.3%$0.99$0.61▼$2.72$65.66M1.25228,923 shs99,770 shsTVTXTravere Therapeutics$23.65+3.9%$18.18$12.91▼$28.69$2.03B0.792.63 million shs2.01 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMTIApplied Molecular Transport0.00%0.00%0.00%0.00%0.00%IMGNImmunoGen0.00%0.00%0.00%0.00%0.00%PRLDPrelude Therapeutics+4.50%-2.52%+33.33%+34.71%-55.38%TVTXTravere Therapeutics-1.04%+5.22%+20.99%+58.02%+59.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMTIApplied Molecular Transport$0.26$0.24$0.13▼$0.84$10.87M2.28470,969 shsN/AIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shs40 shsPRLDPrelude Therapeutics$1.04-10.3%$0.99$0.61▼$2.72$65.66M1.25228,923 shs99,770 shsTVTXTravere Therapeutics$23.65+3.9%$18.18$12.91▼$28.69$2.03B0.792.63 million shs2.01 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMTIApplied Molecular Transport0.00%0.00%0.00%0.00%0.00%IMGNImmunoGen0.00%0.00%0.00%0.00%0.00%PRLDPrelude Therapeutics+4.50%-2.52%+33.33%+34.71%-55.38%TVTXTravere Therapeutics-1.04%+5.22%+20.99%+58.02%+59.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMTIApplied Molecular Transport 0.00N/AN/AN/AIMGNImmunoGen 0.00N/AN/AN/APRLDPrelude Therapeutics 3.00Buy$4.00284.62% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$34.2044.61% UpsideCurrent Analyst Ratings BreakdownLatest IMGN, PRLD, TVTX, and AMTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025TVTXTravere TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$20.00 ➝ $25.009/11/2025TVTXTravere TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$27.00 ➝ $35.009/10/2025TVTXTravere TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.009/10/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.009/3/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.008/28/2025TVTXTravere TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $47.008/18/2025PRLDPrelude TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$4.00 ➝ $3.008/10/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/7/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/7/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$30.00 ➝ $31.008/7/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$30.00 ➝ $32.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMTIApplied Molecular TransportN/AN/AN/AN/A$1.56 per shareN/AIMGNImmunoGen$287.61M28.91N/AN/A$0.71 per share43.99PRLDPrelude Therapeutics$7M8.41N/AN/A$2.39 per share0.44TVTXTravere Therapeutics$233.18M9.04N/AN/A$0.76 per share31.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMTIApplied Molecular Transport-$126.32M-$1.90N/AN/AN/AN/A-223.46%-126.91%N/AIMGNImmunoGen-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/APRLDPrelude Therapeutics-$127.17M-$1.64N/AN/AN/AN/A-106.50%-79.07%11/5/2025 (Estimated)TVTXTravere Therapeutics-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)Latest IMGN, PRLD, TVTX, and AMTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PRLDPrelude Therapeutics-$0.45-$0.41+$0.04-$0.41N/AN/A8/6/2025Q2 2025TVTXTravere Therapeutics-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMTIApplied Molecular TransportN/AN/AN/AN/AN/AIMGNImmunoGenN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMTIApplied Molecular TransportN/A4.994.99IMGNImmunoGen0.135.705.65PRLDPrelude TherapeuticsN/A3.683.68TVTXTravere Therapeutics9.502.001.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMTIApplied Molecular Transport41.79%IMGNImmunoGen90.50%PRLDPrelude Therapeutics79.72%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAMTIApplied Molecular Transport15.90%IMGNImmunoGen5.07%PRLDPrelude Therapeutics63.90%TVTXTravere Therapeutics4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMTIApplied Molecular Transport1341.34 million34.76 millionOptionableIMGNImmunoGen277266.26 million252.76 millionOptionablePRLDPrelude Therapeutics12056.60 million20.43 millionOptionableTVTXTravere Therapeutics46089.14 million85.40 millionOptionableIMGN, PRLD, TVTX, and AMTI HeadlinesRecent News About These CompaniesTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $25.00September 14 at 10:43 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Given New $25.00 Price Target at Stifel NicolausSeptember 14 at 3:59 AM | americanbankingnews.comTravere Therapeutics, Inc. $TVTX Shares Sold by AQR Capital Management LLCSeptember 14 at 3:24 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Shares Down 4.8% - Should You Sell?September 13, 2025 | marketbeat.comWells Fargo & Company Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00September 13, 2025 | marketbeat.comWoodline Partners LP Sells 884,278 Shares of Travere Therapeutics, Inc. $TVTXSeptember 13, 2025 | marketbeat.comWells Fargo & Company Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $35.00September 13, 2025 | americanbankingnews.comTravere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGSSeptember 12, 2025 | seekingalpha.comHC Wainwright Reaffirms Buy Rating for Travere Therapeutics (NASDAQ:TVTX)September 12, 2025 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year High - Here's What HappenedSeptember 12, 2025 | marketbeat.comTVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDASeptember 11, 2025 | zacks.comTravere Therapeutics price target raised to $35 from $27 at Wells FargoSeptember 11, 2025 | msn.comTravere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate SubsideSeptember 11, 2025 | insidermonkey.comStrength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?September 11, 2025 | zacks.comTravere rises as FDA says no AdCom required for Filspari label expansionSeptember 10, 2025 | msn.comTravere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug ApplicationSeptember 10, 2025 | msn.comTravere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical ResultsSeptember 10, 2025 | finance.yahoo.comTravere: No AdCom, No Problem - Targeting Big Revenues With FSGS ApprovalSeptember 10, 2025 | seekingalpha.comTraders Purchase High Volume of Call Options on Travere Therapeutics (NASDAQ:TVTX)September 10, 2025 | marketbeat.comWhy Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year HighSeptember 10, 2025 | investors.comTravere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGSSeptember 10, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMGN, PRLD, TVTX, and AMTI Company DescriptionsApplied Molecular Transport NASDAQ:AMTIApplied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.ImmunoGen NASDAQ:IMGNImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.Prelude Therapeutics NASDAQ:PRLD$1.04 -0.12 (-10.34%) Closing price 04:00 PM EasternExtended Trading$1.04 +0.00 (+0.48%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Travere Therapeutics NASDAQ:TVTX$23.65 +0.88 (+3.86%) Closing price 04:00 PM EasternExtended Trading$23.82 +0.17 (+0.74%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
